Nationwide epidemiology and healthcare burden of pediatric anaphylaxis in Thailand: A population-based study, 2019–2023☆ Authors: Dara Mairiang, Rattapon Uppala, Sirapoom Niamsanit, Phanthila Sitthikarnkha, Kaewjai Thepsuthammarat, Porntipa Suebsarakam Published: 2026 ABSTRACT AbstractBackgroundAnaphylaxis is a potentially life-threatening allergic reaction requiring prompt recognition and treatment. Although increasing trends in pediatric anaphylaxis have been reported worldwide, nationwide epidemiological data from Southeast Asia remain limited. This study aimed to investigate the epidemiology, clinical characteristics, and healthcare burden of pediatric anaphylaxis in Thailand using a national administrative database.MethodsWe conducted a nationwide retrospective study using the Thai National Health Security Office database from 2019 to 2023. Children aged 1 month to <18 years hospitalized with anaphylaxis were identified using ICD-10-TM codes. Demographic characteristics, triggers, comorbidities, complications, and outcomes were analyzed. Temporal trends, regional variation, and factors associated with in-hospital mortality were evaluated.ResultsA total of 42,290 pediatric anaphylaxis hospitalizations were identified, increasing from 7877 cases in 2019 to 10,519 in 2023. School-aged children and adolescents accounted for the largest proportion, with male predominance (59.4%). Food-related reactions were more common in younger children, whereas insect-related reactions were more frequent in older age groups. Most patients had favorable outcomes, with a median hospital stay of 1 day and in-hospital mortality of 0.04%. Severe complications and certain comorbidities were associated with increased risk of adverse outcomes. Geographic variation was observed across regions.ConclusionsPediatric anaphylaxis hospitalizations in Thailand increased during the study period, while mortality remained low. Age-related trigger patterns and regional differences highlight the need for improved surveillance, documentation, and targeted prevention strategies.Keywords: Anaphylaxis, Pediatric, Nationwide database, Hospitalization, Mortality Introduction Anaphylaxis is a serious, life-threatening systemic hypersensitivity reaction that is rapid in onset and can be fatal.1 It is diagnosed by the sudden onset of symptoms affecting at least 2 organ systems or a sudden compromise in breathing and/or circulation, with or without skin/mucosal changes.1, 2, 3, 4 The primary pathophysiology of anaphylaxis involves the release of inflammatory mediators from sensitized basophils and mast cells upon allergen exposure. This cascade causes vasodilation, increased vascular permeability, smooth muscle contraction, and mucous secretion, leading to hypotension, airway constriction, and mucosal edema. These effects can compromise respiratory and cardiovascular function, underscoring the importance of prompt recognition and treatment.2, 3, 4 While the fundamental pathophysiology remains consistent across age groups, there are notable differences in anaphylaxis between children and adults. Children are more prone to respiratory compromise and food allergies, whereas adults often experience cardiovascular symptoms and react more to insect venoms and drugs.5, 6, 7 Diagnosis of anaphylaxis in children can be challenging, as infants and young children cannot articulate their symptoms well. Symptoms may also overlap with common illnesses, especially viral infections. Moreover, children heavily rely on caregivers for recognition of anaphylaxis and initial treatment.8, 9, 10 Anaphylaxis in children can have significant impacts due to its potential for rapid progression and life-threatening outcomes if not promptly treated. The effects extend beyond immediate health risks, affecting quality of life and psychological well-being, while also imposing economic burdens on families and healthcare systems.11 Anaphylaxis in Asian populations differs from that in Western countries due to diverse populations, extensive genetic variation, dietary differences, and socio-economic factors. These disparities are observed even within different regions of Asia.12 Previous studies on anaphylaxis in children in Thailand have been limited to single-site investigations, yielding varied results. Research specifically focused on severe anaphylaxis, which has significant impacts on individuals and the healthcare system, is even more limited.7,13, 14, 15, 16, 17, 18 This study aims to fill the knowledge gaps by conducting a retrospective analysis of data from the National Health Security Office (NHSO) from 2019 to 2023. The primary objective of this research is to examine the nationwide data on epidemiology and burden, including complications and comorbidities of pediatric anaphylaxis, with a particular focus on severe anaphylaxis. The secondary objective is to evaluate the trend of anaphylaxis across the years. Conducting this study is vital to address the current knowledge gap regarding pediatric anaphylaxis in Thailand. The findings will facilitate evidence-based improvements in clinical care, enhance preventive strategies, and ultimately reduce complications associated with anaphylactic reactions in Thai children. Materials and methods Study design and participants This nationwide retrospective study analyzed data from the NHSO database, covering pediatric hospitalizations across Thailand from January 1, 2019, to December 31, 2023. The NHSO manages the Universal Coverage (UC) scheme, which provides health services for approximately 72% of Thailand's population.19 The Thai healthcare system comprises public and private hospitals organized into 3 levels. Primary care hospitals deliver basic outpatient services and serve as the first point of contact. Secondary hospitals are equipped for more specialized care, often with pediatric wards, but typically lack a pediatric allergist. Tertiary hospitals act as referral centers and are equipped with pediatric intensive care units (PICUs) and full subspecialist support. Private hospitals vary in capacity; some operate at a tertiary level, while others provide services comparable to secondary facilities. Eligible patients included children aged between 1 month and less than 18 years who were hospitalized with a diagnosis of anaphylaxis. Anaphylaxis cases were identified using the ICD-10-TM codes: T78.0 (Anaphylactic shock due to adverse food reaction), T88.6 (Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered), T78.2 (Anaphylactic shock, unspecified), T80.5 (Anaphylactic shock due to serum). Diagnoses were assigned by attending physicians. Although some variation in clinical coding practices may exist, the NHSO conducts routine audits of submitted claims to verify diagnostic accuracy and minimize misclassification. This study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.20 Demographic data collection Demographic and clinical data were retrieved from the NHSO administrative database. Extracted variables included patient age, sex, year of admission, hospital level, and geographic region. Records with incomplete demographic information were excluded to ensure accurate patient-level analyses. Recurrent admissions were defined as multiple hospitalizations of the same individual within the study period. Because linkage to hospitalizations occurring before the study period was not available, admissions before the observation window could not be captured. Anaphylaxis triggers were categorized using ICD-10-TM codes recorded in the administrative database. Food-related anaphylaxis was identified using code T78.0 (anaphylactic shock due to adverse food reaction). Drug-related anaphylaxis was defined as code T88.6 (anaphylactic reaction due to an adverse effect of a correctly administered drug or medicament). Insect-related anaphylaxis was defined as code T78.2 in combination with T63.4 or external cause codes X23–X25, indicating exposure to venomous insects. Serum-related anaphylaxis was identified using code T80.5 (anaphylactic shock due to serum). Cases coded as T78.2 without accompanying trigger-specific codes were classified as unspecified anaphylaxis. Comorbid conditions were identified using ICD-10-TM diagnostic codes recorded in the administrative database. Asthma and other chronic lower airway diseases were defined using codes J45, J46, and J44. Neurological and developmental disorders were identified using codes G80, G40, G93, and F70–F79. Congenital heart disease was defined by codes Q20–Q28, while malignancy was identified using codes C00–D48. Immunodeficiency disorders were defined by codes D80–D84. Atopic conditions included atopic dermatitis (L20), allergic rhinitis (J30), and other allergic disorders (T78). Malnutrition was identified using codes E40–E46, and failure to thrive was defined as code R62. Mastocytosis was identified using code D47.0. Complications of anaphylaxis were identified using ICD-10-TM diagnosis and procedure codes. Shock was defined by codes R57.0 (cardiogenic shock), R57.1 (hypovolemic shock), R57.8 (other shock), and R57.9 (unspecified shock). Respiratory complications included acute respiratory failure (J96), respiratory collapse (J98.4), use of continuous positive airway pressure (CPAP; procedure code 9390), and endotracheal intubation (procedure codes 96.71, 96.72, and 96.04). Neurological complications included anoxic brain injury (G93.1), encephalopathy (G93.4), and coma (R40). Cardiac complications comprised arrhythmia (I49) and cardiac arrest (I46) or receipt of cardiopulmonary resuscitation (CPR; procedure code 99.66). Organ failure included acute renal failure (N17) and acute liver failure (K72). Outcomes were categorized as survival (alive at discharge) or in-hospital mortality. Length of stay was calculated as the number of hospitalization days per admission. Total hospital costs per admission were also extracted and analyzed. Each hospital admission may carry multiple ICD-10-TM diagnosis codes. For case inclusion, anaphylaxis codes (T78.0, T78.2, T80.5, T88.6) were required to appear as the principal diagnosis. Trigger classification was assigned hierarchically: if a specific trigger code was present alongside T78.2, the specific trigger took precedence; admissions coded as T78.2 without any accompanying trigger-specific code were classified as unspecified anaphylaxis. Comorbidity codes were identified from any diagnostic position. Complication codes were sought in secondary diagnostic positions only to avoid overlap with the principal anaphylaxis diagnosis. A complete list of all ICD-10-TM codes used, including external cause and procedure codes, is provided in Supplementary Table S1. Statistical analyses All statistical analyses were performed using Stata version 18 (StataCorp LLC, College Station, TX, USA). Categorical variables were summarized as frequencies and percentages. Continuous variables were presented as mean ± standard deviation (SD) or median with interquartile range (IQR), as appropriate, based on distribution assessed using the Shapiro–Wilk normality test. The annual hospitalization rate of pediatric anaphylaxis was calculated by dividing the number of anaphylaxis admissions by the total number of pediatric inpatient admissions in the corresponding year and expressed per 100,000 admissions. In-hospital mortality was calculated as the proportion of deaths among anaphylaxis admissions in each year and region. Patients were categorized into 5 predefined age groups (1 month to <1 year, 1 to <5 years, 5 to <10 years, 10 to <15 years, and 15 to <18 years) for age-stratified analyses. Comparisons between groups (survivors vs. non-survivors) were conducted using the chi-square test or Fisher's exact test for categorical variables and the student's t-test or Mann–Whitney U test for continuous variables, as appropriate. A p-value <0.05 was considered statistically significant. Ninety-five percent confidence intervals (95% CIs) for annual hospitalization rates, regional rate and in-hospital mortality were calculated using the exact Poisson method. Odds ratios (OR) with 95% CIs were estimated using univariable logistic regression to quantify associations between patient characteristics and in-hospital mortality. Ethics approval The study was approved by the Human Research Ethics Committee (approval number: HE681673). Data were accessed for research purposes on November 6, 2025. Since all data were de-identified and obtained from a secondary administrative database, informed consent was waived. Results Between 2019 and 2023 in Table 1, a total of 42,290 pediatric hospital admissions with a diagnosis of anaphylaxis were identified. The annual number of admissions increased progressively from 7877 cases (18.6%) in 2019 to 10,519 cases (24.9%) in 2023. Males accounted for 59.4% of cases. Most patients were aged 10–<15 years (35.9%), followed by 15–<18 years (26.3%) and 5–<10 years (25.6%). Geographically, the Northeast region had the highest proportion of admissions (32.9%), followed by the Central region (25.1%). Most patients were treated in secondary-level hospitals (76.7%). The most common diagnostic category was unspecified anaphylaxis (66.7%), while food-induced (24.0%) and insect-related anaphylaxis (22.6%) were the most identified triggers. Atopic conditions were recorded in 97.7% of patients. Complications were rare overall; respiratory failure occurred in 0.4%, and in-hospital mortality was 0.04% (this figure reflects in-hospital deaths only; pre-hospital fatalities are not captured in the NHSO database). The median length of stay was 1 day (IQR 1–2), and the median hospitalization cost was 2186 Baht. Table 1Baseline characteristics of pediatric patients hospitalized with anaphylaxis (n = 42,290).Table 1Characteristicn (%)A. Demographic CharacteristicsTotal cases42,290 (100.0)Year 20197877 (18.6) 20207473 (17.7) 20217509 (17.8) 20228912 (21.1) 202310,519 (24.9)Sex Male25,100 (59.4) Female17,190 (40.6)Age group 1 month – <1 year508 (1.2) 1 – <5 years4636 (11.0) 5 – <10 years10,842 (25.6) 10 – <15 years15,182 (35.9) 15 – <18 years11,122 (26.3)Geographic region Bangkok970 (2.3) Central10,608 (25.1) Northeast13,892 (32.9) North7583 (17.9) South9237 (21.8)Hospital level Primary3508 (8.3) Secondary32,424 (76.7) Tertiary6049 (14.3) Private309 (0.7)B. Trigger CategoryFood-induced anaphylaxis10,142 (24.0)Drug-induced anaphylaxis880 (2.1)Insect-induced anaphylaxis9569 (22.6)Serum-related anaphylaxis132 (0.3)Anaphylaxis unspecified28,188 (66.7)C. Comorbid ConditionsAsthma755 (1.8)Neurological / developmental disorder131 (0.3)Congenital heart disease76 (0.2)Malignancy228 (0.5)Immunodeficiency13 (0.03)Atopy41,302 (97.7)Malnutrition / failure to thrive73 (0.2)Mastocytosis0 (0.0)D. Complications of AnaphylaxisAnaphylactic shock27 (0.1)Need for CPAP91 (0.2)Respiratory failure146 (0.4)Encephalopathy12 (0.03)Arrhythmias10 (0.02)Cardiac arrest9 (0.02)Organ failure118 (0.3)E. Clinical OutcomesSurvived (discharged alive)42,271 (99.96)In-hospital death19 (0.04)Length of stay, median (IQR) days1 (1–2)Hospital cost, median (IQR) Baht2186 (1576–3166)Data are presented as n (%) unless otherwise indicated.Abbreviations: CPAP, continuous positive airway pressure; IQR, interquartile range Baseline characteristics of pediatric patients hospitalized with anaphylaxis (n = 42,290). Data are presented as n (%) unless otherwise indicated. Abbreviations: CPAP, continuous positive airway pressure; IQR, interquartile range The triggers of pediatric anaphylaxis by age group is shown in Table 2. Food-induced anaphylaxis was most common among infants (44.3% in 1 month–<1 year). Insect-related anaphylaxis increased with age, particularly in children aged 5–<10 years (27.4%). Drug-related anaphylaxis remained low across all age groups (1.9–3.9%). Unspecified anaphylaxis accounted for approximately two-thirds of cases in most age groups. Table 2Triggers of pediatric anaphylaxis by age group, Thailand 2019–2023.Table 2Age groupFood-induced anaphylaxis (n = 10,142), n (%)Drug-induced anaphylaxis (n = 880), n (%)Insect-induced anaphylaxis (n = 9569), n (%)Serum-related anaphylaxis (n = 132), n (%)Anaphylaxis unspecified (n = 28,188), n (%)1 month–<1 year225 (44.3)20 (3.9)23 (4.5)2 (0.4)249 (49.0)1–<5 years1073 (23.1)131 (2.8)1140 (24.6)14 (0.3)3052 (65.8)5–<10 years2465 (22.7)207 (1.9)2967 (27.4)37 (0.3)7222 (66.6)10–<15 years3647 (24.0)295 (1.9)3280 (21.6)52 (0.3)10,193 (67.1)15–<18 years2732 (24.6)227 (2.0)2159 (19.4)27 (0.2)7472 (67.2)Data are presented as n (%) unless otherwise indicated. Percentages are calculated within each age group (row totals may not sum to 100% due to overlap or rounding) Triggers of pediatric anaphylaxis by age group, Thailand 2019–2023. Data are presented as n (%) unless otherwise indicated. Percentages are calculated within each age group (row totals may not sum to 100% due to overlap or rounding) The annual hospitalization rate and in-hospital mortality rate of pediatric anaphylaxis are presented in Table 3. The hospitalization rate increased steadily from 435.8 per 100,000 admissions in 2019 to 770.5 per 100,000 admissions in 2023, while overall mortality remained below 1% annually. Regionally, hospitalization rates increased across all geographic areas from 2019 to 2023 (Table 4). The highest rates were observed in the southern regions, reaching 945.2 per 100,000 admissions in 2023. In contrast, Bangkok consistently had the lowest hospitalization rates throughout the study period, despite a modest increase from 185.0 per 100,000 admissions in 2019 to 215.5 per 100,000 admissions in 2022. As shown in Table 5, Bangkok exhibited relatively higher mortality rates in the early years of the study, although these declined after 2021. Table 3Annual trends in pediatric anaphylaxis hospitalization rate, in-hospital mortality, and proportion of unspecified anaphylaxis, Thailand 2019–2023.Table 3YearCases, nHospitalization rate (per 100,000 admissions)95%CI of hospitalization rate (per 100,000 admission)Deaths, nMortality rate (per 1000 admissions)95% CI of mortality rate (per 1000 admission)Unspecified anaphylaxis, nUnspecified anaphylaxis, %20197877435.8426.2–445.540.510.14–1.30544419.320207473524.4512.6–536.440.540.15–1.37493117.520217509568.4555.6–581.450.670.22–1.55490617.420228912655.8642.3–669.610.110.003–0.63601721.4202310,519770.5755.8–785.450.480.15–1.11689024.4Total42,290595.5589.8–601.2190.450.27–0.7028,18866.7Data are presented as n (%) unless otherwise indicated Annual trends in pediatric anaphylaxis hospitalization rate, in-hospital mortality, and proportion of unspecified anaphylaxis, Thailand 2019–2023. Data are presented as n (%) unless otherwise indicated Table 4Annual hospitalization rate of pediatric anaphylaxis by geographic region (per 100,000 admissions)Table 4YearTotal (95%CI)Bangkok (95%CI)Central (95%CI)Northeast (95%CI)North (95%CI)South (95%CI)2019435.8 (426.2–445.5)185.0 (160.3–212.4)507.8 (486.4–529.9)386.5 (371.3–402.1)486.7 (462.0–512.4)473.3 (450.9–496.6)2020524.4 (512.6–536.4)247.9 (216.2–283.0)586.4 (560.5–613.2)468.6 (450.0–487.7)573.8 (543.6–605.2)605.3 (575.8–635.9)2021568.4 (555.6–581.4196.0 (167.1–228.5)546.2 (521.2–572.0)621.0 (597.2–645.5)675.8 (640.9–712.1)547.9 (521.1–575.7)2022655.8 (642.3–669.6)215.5 (186.2–248.1)665.4 (637.9–693.8)622.6 (600.3–645.5)753.1 (717.2–790.3)781.6 (747.0–817.4)2023770.5 (755.8–785.4)246.1 (212.6–283.4)823.3 (791.8–855.7)731.1 (707.2–755.6)759.0 (723.6–795.7)945.2 (908.5–983.0) Annual hospitalization rate of pediatric anaphylaxis by geographic region (per 100,000 admissions) Table 5Annual in-hospital mortality of pediatric anaphylaxis by geographic region (per 1000 anaphylaxis admissions)Table 5YearRegionAdmissions (n)Mortality rate (per 1000 admissions)95% CI2019Bangkok2015.00.1- 27.7Central21131.40.3 -4.1Northeast24410.00.0–1.5North14540.00.0–2.5South16680.00.0–2.22020Bangkok2194.60.1–25.4Central19200.00.0–1.9Northeast24020.80.1–3.0North13510.70.0–4.1South15810.00.0–2.32021Bangkok1636.10.2–34.2Central17981.10.1–4.0Northeast25730.80.1–2.8North14050.00.0–2.6South15700.00.0–2.32022Bangkok1940.00.0–19.0Central22010.50.0–2.5Northeast29490.00.0–1.3North16490.00.0–2.2South19190.00.0–1.92023Bangkok1930.00.0–19.1Central25760.80.1–2.8Northeast35270.60.1–2.0North17240.00.0–2.1South24990.40.0–2.2 Annual in-hospital mortality of pediatric anaphylaxis by geographic region (per 1000 anaphylaxis admissions) As shown in Table 3, unspecified anaphylaxis accounted for 28,188 cases (66.7% of all pediatric anaphylaxis hospitalizations). Its proportion decreased slightly during the COVID-19 pandemic years, from 19.3% in 2019 to 17.5% and 17.4% in 2020 and 2021, respectively, before increasing to 21.4% in 2022 and 24.4% in 2023. Factors associated with in-hospital mortality in pediatric anaphylaxis is shown in Table 6. Nineteen deaths (0.04%) occurred. Children who died were significantly younger than survivors (mean age 7.1 ± 5.5 vs. 10.7 ± 4.6 years, p = 0.005). Increasing age was associated with lower mortality (OR 0.86, 95% CI 0.77–0.96, p = 0.005). Mortality was more frequent among children aged 1 year–<5 years. Drug-related anaphylaxis and serum-related anaphylaxis were significantly associated with mortality. Comorbid neurodevelopmental disorders, congenital heart disease, malignancy, and atopy were also significantly associated. Severe complications, including shock, respiratory failure, encephalopathy, arrhythmias, organ failure, need for intubation, central venous catheter insertion, and renal replacement therapy, were strongly associated with death (p < 0.001). Length of stay was significantly longer among deceased patients than survivors (median 9 days vs. 1 day, p < 0.001). Longer hospital stay was associated with increased mortality (OR 1.06, 95% CI 1.04–1.07). Table 6Factors associated with in-hospital mortality in pediatric anaphylaxis.Table 6CharacteristicAll (n = 42,290), n (%)Survivors (n = 42,271), n (%)Deaths (n = 19), n (%)p-valueOR (95% CI)Age at diagnosis (years), mean ± SD10.7 ± 4.610.7 ± 4.67.1 ± 5.50.0050.85 (0.76, 0.95) Male sex25,100 (59.4)25,090 (59.4)10 (52.6)0.5520.76 (0.31, 1.87) Age group, n (%)0.002 1 month – <1 year508 (1.2)507 (1.2)1 (5.3)1 1 – <5 years4636 (11.0)4628 (11.0)8 (42.1)0.88 (0.11, 7.02) 5 – <10 years10,842 (25.6)10,840 (25.6)2 (10.5)0.09 (0.01, 1.03) 10 – <15 years15,182 (35.9)15,175 (35.9)7 (36.8)0.23 (0.03, 1.90) 15 – <18 years11,122 (26.3)11,121 (26.3)1 (5.3)0.05 (0.00, 0.73)Geographic region, n (%)0.007 Bangkok970 (2.3)967 (2.3)3 (15.8)1 Central10,608 (25.1)10,600 (25.1)8 (42.1)0.24 (0.06, 0.92) Northeast13,892 (32.9)13,886 (32.9)6 (31.6)0.14 (0.03, 0.56) North7583 (17.9)7582 (17.9)1 (5.3)0.04 (0.00, 0.41) South9237 (21.8)9236 (21.8)1 (5.3)0.03 (0.00, 0.34)Hospital level, n (%)<0.001 Primary3508 (8.3)3508 (8.3)0 (0.0)1 Secondary32,424 (76.7)32,417 (76.7)7 (36.8)0.11 (0.04, 0.28) Tertiary6049 (14.3)6037 (14.3)12 (63.2)NA Private309 (0.7)309 (0.7)0 (0.0)NATrigger category Food-induced anaphylaxis10,142 (24.0)10,142 (24.0)0 (0.0)NA Drug-induced anaphylaxis880 (2.1)875 (2.1)5 (26.3)<0.00116.90 (6.07, 47.02) Insect-induced anaphylaxis9569 (22.6)9567 (22.6)2 (10.5)0.2230.40 (0.09, 1.74) Serum-related anaphylaxis132 (0.3)129 (0.3)3 (15.8)<0.00161.25 (17.70, 211.94) Unspecified anaphylaxis28,188(66.7)28,179(66.7)9(47.4)0.0820.45 (0.18, 1.11)Comorbid conditions Asthma755 (1.8)755 (1.8)0 (0.0)NA Neurological / developmental disorder131 (0.3)129 (0.3)2 (10.5)<0.00138.43 (8.78, 168.23) Congenital heart disease76 (0.2)75 (0.2)1 (5.3)0.00131.26 (4.11, 237.69) Malignancy228 (0.5)224 (0.5)4 (21.1)<0.00150.06 (16.49, 151.98) Immunodeficiency13 (0.0)13 (0.0)0 (0.0)NA Atopy41,302 (97.7)41,291 (97.7)11 (57.9)<0.0010.03 (0.01, 0.08) Malnutrition / failure to thrive73 (0.2)73 (0.2)0 (0.0)NA Mastocytosis0 (0.0)0 (0.0)0 (0.0)NAComplications of anaphylaxis Shock27 (0.1)26 (0.1)1 (5.3)<0.00190.27 (11.62, 701.23) Respiratory failure146 (0.4)133 (0.3)13 (68.4)<0.001686.46 (256.45, 1837.40) Encephalopathy12 (0.0)11 (0.0)1 (5.3)<0.001213.43 (26.17, 1740.58) Arrhythmias10 (0.0)9 (0.0)1 (5.3)<0.001260.88 (31.41, 2166.96) Organ failure118 (0.3)113 (0.3)5 (26.3)<0.001133.24 (47.15, 376.55)Intubation, n (%)130 (0.3)117 (0.3)13 (68.4)<0.001780.63 (290.93, 2094.62)Central venous catheter insertion, n (%)72 (0.2)68 (0.2)4 (21.1)<0.001165.50 (53.51, 511.86)Renal replacement therapy, n (%)16 (0.0)14 (0.0)2 (10.5)<0.001355.10 (74.92, 1683.15)Length of stay, days, median (IQR)1 (1–2)1 (1–2)9 (1–23)<0.0011.06 (1.04, 1.07)Data are presented as n (%) unless otherwise indicated.Abbreviations: CI, confidence interval; IQR, interquartile range; OR, odds ratio; SD, standard deviation Factors associated with in-hospital mortality in pediatric anaphylaxis. Data are presented as n (%) unless otherwise indicated. Abbreviations: CI, confidence interval; IQR, interquartile range; OR, odds ratio; SD, standard deviation Discussion This nationwide population-based study provides the first comprehensive national epidemiological analysis of pediatric anaphylaxis in Thailand using a large administrative healthcare database. The findings demonstrate a steadily increasing burden of pediatric anaphylaxis hospitalizations over recent years. These results highlight that anaphylaxis represents an emerging public health concern in pediatric populations, not only in Western countries but also in rapidly developing regions of Southeast Asia.16,21, 22, 23 Despite the increasing prevalence and hospitalization rates, overall mortality remains rare, consistent with previous studies reporting low fatality rates among pediatric anaphylaxis cases.21 These findings contribute important epidemiological data from Southeast Asia, a region where national-level pediatric anaphylaxis data remain scarce. The increasing trend observed in this study is consistent with global epidemiological reports describing a rising incidence of anaphylaxis worldwide.16, 17, 18,22,23 Multiple factors may contribute to this pattern, including the increasing prevalence of allergic diseases, greater awareness among healthcare providers, and improvements in diagnostic recognition and coding practices. The age-related trigger patterns observed in this study also align with previous pediatric cohorts internationally, where food-induced reactions are more common in early childhood, while insect-related reactions become increasingly relevant in older children.6,23,24 A notable finding was the high proportion of unspecified anaphylaxis diagnoses. Similar patterns have been reported in large administrative database studies in other countries, where detailed allergen identification may not be documented during acute hospital encounters.22 This observation underscores an important gap in clinical documentation and suggests that improved allergen identification and post-discharge allergy evaluation could enhance surveillance accuracy and guide preventive strategies. We additionally examined temporal trends in unspecified anaphylaxis because changes in healthcare utilization during the COVID-19 pandemic may have influenced diagnostic coding. The proportion of unspecified anaphylaxis decreased slightly during 2020–2021 (17.5%–17.4%) compared with 2019 (19.3%), but increased thereafter to 24.4% in 2023. While reduced exposures during lockdown periods may have facilitated identification of culprit allergens, the subsequent increase is more likely attributable to increasing case volume, variations in coding practices, and incomplete documentation of triggers in administrative databases. Therefore, unspecified anaphylaxis should not be considered equivalent to idiopathic anaphylaxis. Fatal anaphylaxis in children is uncommon but remains a preventable cause of death that warrants ongoing clinical attention. Globally, case fatality rates from anaphylaxis hospitalizations have been estimated at approximately 0.5–1%, with consistent findings across multiple international administrative database studies.22 Importantly, Turner et al demonstrated in a large UK national dataset that despite a marked increase in anaphylaxis-related hospitalizations over 2 decades, fatality rates did not rise correspondingly, suggesting that improved recognition and acute management may have contained mortality even as overall disease burden grew.21 Our findings are consistent with this dissociation: while hospitalization rates nearly doubled over the study period, annual in-hospital mortality remained below 1% throughout, with no discernible upward trend. The in-hospital mortality rate of 0.04% in the present study is notably lower than some reported estimates, which may partly reflect the inclusion of a large proportion of mild or moderate admissions in a nationwide database, as well as the predominantly young and otherwise healthy nature of the pediatric population studied. From a pathophysiological standpoint, fatal anaphylaxis in children predominantly results from acute respiratory compromise — including bronchospasm, laryngeal edema, and respiratory failure — rather than from primary cardiovascular collapse, a pattern corroborated by our finding that respiratory failure was the most frequent severe complication among deceased patients.21,22 Published fatality registers have consistently identified delayed or absent epinephrine administration as the most critical modifiable risk factor for fatal anaphylaxis, yet this important variable could not be captured from our administrative database.21 This limitation reinforces the need to link administrative data with clinical records or prospective registries to fully characterize the determinants of fatal pediatric anaphylaxis in Thailand. Importantly, our reported in-hospital mortality of 0.04% likely underestimates the true case fatality rate, as deaths occurring before hospital arrival — which may be particularly relevant in areas with limited emergency medical services — are not captured in the NHSO database. This limitation should be considered when interpreting our mortality data relative to international estimates. Regional variation in anaphylaxis hospitalization rates was also observed across Thailand. Geographic differences in anaphylaxis epidemiology have been reported internationally and may reflect variations in environmental exposures, dietary habits, insect distribution, healthcare access, and diagnostic practices.12,22,24 The regional differences observed in this study may reflect variations in environmental exposures, dietary practices, and healthcare access across Thailand. The Northeast region, which recorded the highest proportion of anaphylaxis admissions (32.9%), is predominantly rural and agricultural, potentially resulting in greater exposure to insects and other environmental triggers. The Central region, encompassing Bangkok and surrounding provinces, is the most urbanized area of the country and has the highest concentration of tertiary-care facilities, which may facilitate the recognition and hospitalization of anaphylaxis cases. The Northern region is characterized by mountainous geography and distinct local dietary patterns, while the Southern region has relatively high seafood consumption and unique environmental exposures that may influence the distribution of allergic triggers. Collectively, these regional differences may contribute to the geographic heterogeneity observed in our study and should be considered when developing region-specific strategies for the prevention and management of anaphylaxis. The strengths of this study include the use of a nationwide healthcare database covering most pediatric hospitalizations in Thailand, providing strong population representativeness and statistical power. In addition to describing epidemiological patterns, the study also evaluated indicators of healthcare burden, including complications, procedures, length of stay, and hospitalization costs, offering valuable insight into the healthcare impact of pediatric anaphylaxis. However, several limitations should be acknowledged. As an administrative database analysis, this study relied on diagnostic coding, which may introduce misclassification bias. Detailed clinical information, including symptom severity, administration of adrenaline, timing of epinephrine treatment, and allergen confirmation testing, was not available. The high proportion of unspecified diagnoses suggests that triggers may have been under-documented during acute hospital care. In addition, the small number of fatal cases limited the statistical power of the mortality analysis. Furthermore, the NHSO database captures only hospitalized patients. Fatal anaphylactic reactions occurring before hospital arrival are not recorded and therefore could not be assessed in this study. Variability in access to emergency medical services across Thailand, particularly in rural settings, may have limited hospital presentation for some severe cases. Consequently, anaphylaxis-related mortality may be underestimated in our dataset, and comparisons with mortality estimates derived from prospective surveillance systems or death registry–based studies should be interpreted with caution. As the NHSO database covers Thai nationals enrolled in the Universal Coverage scheme, the dataset does not include international tourists, foreign nationals, or individuals covered by alternative insurance schemes, and the true burden of anaphylaxis among all individuals present in the country may be higher than our estimates suggest. Additionally, the metric used — annual hospitalization rate per 100,000 pediatric admissions — reflects hospital utilization patterns and should not be interpreted as a true population incidence rate. Despite these limitations, this study provides important national evidence on pediatric anaphylaxis in Thailand and contributes to the limited epidemiological data available from Southeast Asia. The findings highlight the need for improved surveillance systems, better trigger documentation, and strengthened referral pathways for allergy evaluation following acute episodes. Conclusions In conclusion, this nationwide study demonstrates a rising burden of pediatric anaphylaxis hospitalizations in Thailand over recent years, reflecting the growing impact of allergic diseases in children. Although mortality remains uncommon, severe complications continue to occur and require prompt recognition and management. Strengthening national surveillance systems, improving allergen identification, and expanding access to specialized allergy care may help reduce preventable morbidity and improve outcomes for children with anaphylaxis. Author contributions Conceptualization: Porntipa Suebsarakam, Rattapon Uppala, Dara Mairiang. Data curation: Porntipa Suebsarakam, Dara Mairiang, Sirapoom Niamsanit, Phanthila Sitthikarnkha. Formal analysis: Kaewjai Thepsuthammarat. Writing – original draft: Porntipa Suebsarakam. Writing – review and editing: All authors approved the final manuscript. Disclosure of the use of generative AI and AI-assisted technologies During the preparation of this work, the authors used ChatGPT (OpenAI) to improve language and readability. The authors reviewed and edited the content as needed and take full responsibility for the content of the publication. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest The authors declare no conflicts of interest. Footnotes Full list of author information is available at the end of the article Supplementary data to this article can be found online at https://doi.org/10.1016/j.waojou.2026.101437. Supplementary data The following is the Supplementary data to this article: Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1